

1

Fiscal quarter ended December 2017 – supplementary financial summary –

February 7, 2018 Asahi Kasei Corporation

Contents

Consolidated results for fiscal quarter ended Dec. 2017

| Summary of financial results | 4 |
|---|-------|
| Statements of income | 5 |
| Extraordinary income and loss | 6 |
| Balance sheets | 7 |
| Cash flows | 8 |
| Sales and operating income by segment | 9–10 |
| Sales and operating income by business category | 11–14 |

Forecast for fiscal year 2017

| Consolidated operating performance forecast | 16 |
|---|-------|
| Forecast by business category | 17–18 |
| Forecast by segment | 19 |
| Appendix | |
| Performance by business category | 21–22 |
| Overseas sales by business category | 23 |
| Statements of comprehensive income | 24 |
| Overview of results by business category | 25–34 |

<u>Disclaimer</u> The forecasts and estimates shown in this document are dependent on a variety of assumptions and economic conditions. Plans and figures depicting the future do not imply a guarantee of actual outcomes.



Consolidated results for fiscal quarter ended Dec. 2017

Period from April 1 to December 31, 2017,

and October 1 to December 31, 2017.

Summary of financial results



(¥ billion)

| | 2016 | | 2017 | | | OctDec. 2017 vs. 2016 | | Apr.–Dec. 2017 vs. 2016 | | % of forecast |
|---|-----------|-----------|----------------------|---------|------------------------|--------------------------|------------------------|----------------------------|--------------|------------------|
| | Oct.–Dec. | Apr.–Dec. | Dec. OctDec. AprDec. | | Increase (decrease) | % change | Increase (decrease) | % change | in Nov. b | a/b |
| Net sales | 466.1 | 1,356.8 | 519.8 | 1,484.5 | 53.7 | +11.5% | 127.7 | +9.4% | 2,000.0 | 74.2% |
| Operating income | 43.4 | 114.1 | 56.5 | 149.2 | 13.2 | +30.4% | 35.1 | +30.7% | 183.0 | 81.5% |
| Ordinary income | 48.5 | 118.4 | 62.4 | 160.5 | 13.8 | +28.5% | 42.2 | +35.6% | 192.0 | 83.6% |
| Net income attributable to owners of the parent | 36.7 | 89.7 | 69.5 | 140.3 | 32.7 | +89.1% | 50.7 | +56.5% | 140.0 | 100.2% |

Key operating factors

| Naphtha price (¥/kL, domestic) | 34,000 | 32,300 | 44,600 | 39,933 |
|--|--------|--------|--------|--------|
| ¥/US\$ exchange rate (market average) | 109 | 107 | 113 | 112 |
| ¥/€ exchange rate (market average) | 118 | 118 | 133 | 129 |

Financial position

| | At end of Mar. 2017 | At end of Dec. 2017 | Increase (decrease) |
|-----------------------|------------------------|------------------------|------------------------|
| Total assets | 2,254.5 | 2,422.5 | 168.0 |
| Equity | 1,151.3 | 1,300.6 | 149.3 |
| Interest-bearing debt | 402.8 | 402.3 | (0.5) |
| Debt/equity ratio | 0.35 | 0.31 | (0.04) |

Statements of income

Asahi KASEI

(¥ billion)

| | | 20 |)16 | | | 20 |)17 | | Oct 2017 v | | Apr 2017 v | |
|---|------------|---------------------|------------|---------------------|------------|---------------------|------------|---------------------|------------------------|----------|------------------------|----------|
| | Oct | -Dec. % of sales | Apr | -Dec. % of sales | Oct. | -Dec. % of sales | Apr. | -Dec. % of sales | Increase (decrease) | % change | Increase (decrease) | % change |
| Net sales | 466.1 | 100.0% | 1,356.8 | 100.0% | 519.8 | 100.0% | 1,484.5 | 100.0% | 53.7 | +11.5% | 127.7 | +9.4% |
| Cost of sales | 317.8 | 68.2% | 928.7 | 68.4% | 351.0 | 67.5% | 1,002.5 | 67.5% | 33.2 | +10.4% | 73.8 | +8.0% |
| Gross profit | 148.4 | 31.8% | 428.2 | 31.6% | 168.8 | 32.5% | 482.0 | 32.5% | 20.5 | +13.8% | 53.9 | +12.6% |
| Selling, general and administrative expenses | 105.0 | 22.5% | 314.0 | 23.1% | 112.3 | 21.6% | 332.8 | 22.4% | 7.3 | +7.0% | 18.8 | +6.0% |
| Operating income | 43.4 | 9.3% | 114.1 | 8.4% | 56.5 | 10.9% | 149.2 | 10.0% | 13.2 | +30.4% | 35.1 | +30.7% |
| Net non-operating income (expenses) of which, | 5.2 | | 4.3 | | 5.8 | | 11.4 | | 0.7 | | 7.1 | |
| net financing income (expenses) net equity in earnings (losses) of affiliates | 0.6 1.3 | | 1.7 2.6 | | 2.2 3.8 | | 3.6 9.1 | | 1.5 2.5 | | 1.9 6.5 | |
| foreign exchange gains (loss) | 3.6 | | 0.3 | | (0.6) | | (1.5) | | (4.2) | | (1.8) | |
| Ordinary income | 48.5 | 10.4% | 118.4 | 8.7% | 62.4 | 12.0% | 160.5 | 10.8% | 13.8 | +28.5% | 42.2 | +35.6% |
| Net extraordinary income (loss) | 2.2 | | 3.0 | | 7.3 | | 10.8 | | 5.1 | | 7.8 | |
| Income before income taxes | 50.7 | 10.9% | 121.4 | 8.9% | 69.7 | 13.4% | 171.4 | 11.5% | 19.0 | +37.4% | 50.0 | +41.1% |
| Total Income taxes | (13.5) | | (30.4) | | 0.3 | | (29.5) | | 13.7 | | 1.0 | |
| Net income attributable to non-controlling interests | (0.5) | | (1.3) | | (0.5) | | (1.6) | | 0.0 | | (0.2) | |
| Net income attributable to owners of the parent | 36.7 | 7.9% | 89.7 | 6.6% | 69.5 | 13.4% | 140.3 | 9.5% | 32.7 | +89.1% | 50.7 | +56.5% |



(¥ billion)

| | | | | | | | . , |
|---|--|-----------|-----------|-----------|-----------|-------------|-------------|
| | | 20 | 16 | 20 | 17 | Oct.–Dec. | Apr.–Dec. |
| | | | | | | '17 vs. '16 | '17 vs. '16 |
| | | Oct.–Dec. | Apr.–Dec. | Oct.–Dec. | Apr.–Dec. | Increase | Increase |
| | | | | | | (decrease) | (decrease) |
| | Gain on sales of investment securities | 6.0 | 9.9 | 9.2 | 15.1 | 3.3 | 5.2 |
| | Gain on sales of noncurrent assets | 0.0 | 0.1 | 0.1 | 0.5 | 0.1 | 0.5 |
| | Total extraordinary income | 6.0 | 9.9 | 9.4 | 15.6 | 3.3 | 5.7 |
| | Loss on valuation of investment securities | 0.0 | 0.0 | 0.0 | 0.0 | (0.0) | (0.0) |
| | Loss on disposal of noncurrent assets | 1.0 | 2.3 | 1.4 | 2.9 | 0.4 | 0.6 |
| | Impairment loss | 0.0 | 0.1 | 0.3 | 0.9 | 0.3 | 0.8 |
| | Business structure improvement expenses | 2.8 | 3.8 | 0.4 | 1.1 | (2.4) | (2.8) |
| | Business integration expense | 0.0 | 0.7 | _ | — | (0.0) | (0.7) |
| | Total extraordinary loss | 3.8 | 6.9 | 2.0 | 4.8 | (1.8) | (2.1) |
| N | let extraordinary income (loss) | 2.2 | 3.0 | 7.3 | 10.8 | 5.1 | 7.8 |

Balance sheets

Asahi KASEI

| | | | - | | | | (¥ billion) |
|-------------------------------------|------------------------|------------------------|------------------------|--|------------------------|------------------------|------------------------|
| | At end of Mar. 2017 | At end of Dec. 2017 | Increase (decrease) | | At end of Mar. 2017 | At end of Dec. 2017 | Increase (decrease) |
| Current assets | 894.5 | 1,018.5 | 124.0 | Liabilities | 1,086.4 | 1,103.9 | 17.5 |
| Cash and deposits | 145.3 | 192.6 | 47.3 | Current liabilities | 594.9 | 635.2 | 40.3 |
| Notes and accounts receivable-trade | 302.8 | 334.9 | 32.1 | Noncurrent liabilities | 491.5 | 468.7 | (22.8) |
| Inventories | 346.7 | 384.5 | 37.8 | Net assets | 1,168.1 | 1,318.6 | 150.5 |
| Other current assets | 99.8 | 106.5 | 6.7 | Shareholders' equity | 1,030.1 | 1,130.9 | 100.8 |
| Noncurrent assets | 1,360.0 | 1,404.0 | 44.0 | Capital stock | 103.4 | 103.4 | - |
| Property, plant and equipment | 556.9 | 565.8 | 9.0 | Capital surplus | 79.4 | 79.4 | (0.0) |
| Intangible assets | 462.8 | 444.8 | (17.9) | Retained earnings | 850.5 | 952.0 | 101.5 |
| Investments and other assets | 340.3 | 393.3 | 53.0 | Treasury stock | (3.2) | (3.9) | (0.7) |
| | | | | Accumulated other comprehensive income | 121.2 | 169.7 | 48.4 |
| | | | | Non-controlling interests | 16.8 | 18.0 | 1.3 |
| Total assets | 2,254.5 | 2,422.5 | 168.0 | Total liabilities and net assets | 2,254.5 | 2,422.5 | 168.0 |



| | | | | (¥ billion) |
|---|---------|-----------|---------|-------------|
| | 20 | 16 | 20 | 17 |
| | OctDec. | Apr.–Dec. | OctDec. | AprDec. |
| a. Net cash provided by (used in) operating activities | 33.2 | 123.7 | 39.0 | 154.0 |
| b. Net cash provided by (used in) investing activities | (12.6) | (63.1) | (16.1) | (69.1) |
| c. Free cash flows [a+b] | 20.7 | 60.6 | 22.9 | 85.0 |
| d. Net cash provided by (used in) financing activities | 29.9 | (13.4) | 2.8 | (43.1) |
| e. Effect of exchange rate change on cash and cash equivalents | 4.9 | (5.1) | 4.0 | 5.1 |
| f. Net increase (decrease) in cash and cash equivalents [c+d+e] | 55.4 | 42.0 | 29.7 | 47.0 |
| g. Cash and cash equivalents at beginning of period | 132.3 | 145.3 | 161.6 | 144.1 |
| h. Increase in cash and cash equivalents resulting from changes in scope of consolidation | _ | 0.4 | _ | 0.3 |
| i. Cash and cash equivalents at end of period [f+g+h] | 187.8 | 187.8 | 191.3 | 191.3 |



(¥ billion)

| | | Sales | | Operating income | | | | |
|-------------------------------------|-----------|-----------|------------|------------------|-----------|------------|--|--|
| | Oct.–Dec. | Oct.–Dec. | Increase | Oct.–Dec. | Oct.–Dec. | Increase | | |
| | 2016 | 2017 | (decrease) | 2016 | 2017 | (decrease) | | |
| Material ¹ | 253.0 | 288.6 | 35.6 | 27.4 | 36.8 | 9.4 | | |
| Homes | 139.5 | 149.3 | 9.7 | 12.4 | 13.3 | 0.9 | | |
| Health Care | 69.1 | 77.5 | 8.5 | 9.4 | 13.5 | 4.2 | | |
| Others ¹ | 4.5 | 4.4 | (0.1) | 0.4 | 0.4 | 0.0 | | |
| Corporate expenses and eliminations | _ | _ | _ | (6.3) | (7.5) | (1.2) | | |
| Consolidated | 466.1 | 519.8 | 53.7 | 43.4 | 56.5 | 13.2 | | |

¹ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Material business category. FY 2016 figures are recalculated in accordance with the new classification.



(¥ billion)

| | | Sales | | Oŗ | Operating income | | | |
|-------------------------------------|-------------------|-------------------|------------------------|-------------------|-------------------|------------------------|--|--|
| | Apr.–Dec. 2016 | Apr.–Dec. 2017 | Increase (decrease) | Apr.–Dec. 2016 | Apr.–Dec. 2017 | Increase (decrease) | | |
| | 2010 | 2017 | (decrease) | 2010 | 2017 | (decrease) | | |
| Material ¹ | 717.0 | 807.5 | 90.6 | 66.4 | 97.5 | 31.2 | | |
| Homes | 427.0 | 445.0 | 18.0 | 38.9 | 39.4 | 0.5 | | |
| Health Care | 201.4 | 220.0 | 18.7 | 26.9 | 32.0 | 5.0 | | |
| Others ¹ | 11.5 | 12.0 | 0.5 | 1.3 | 1.1 | (0.2) | | |
| Corporate expenses and eliminations | I | I | - | (19.3) | (20.8) | (1.5) | | |
| Consolidated | 1,356.8 | 1,484.5 | 127.7 | 114.1 | 149.2 | 35.1 | | |

¹ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Material business category. FY 2016 figures are recalculated in accordance with the new classification.

Sales and operating income increase/decrease by business category¹, Oct.–Dec. 2017 vs. 2016 (i) Asahi**KASEI**

(¥ billion)

| | | | | Not | | Increa | ase (decrease | e) due to | : | |
|------------------------|------------------|-------------------|-------------------|-------------------------------|-----------------|-----------------|---|-----------|----------------------------------|---|
| | | Oct.–Dec. 2016 | Oct.–Dec. 2017 | Net increase (decrease) | Sales volume | Sales prices | of which, due to foreign exchange | Others | Operating costs and others | |
| Fibers | Sales | 31.4 | 34.7 | 3.3 | 1.9 | 0.6 | 0.2 | 0.9 | _ | |
| Fibers | Operating income | 3.4 | 3.0 | (0.3) | 0.6 | 0.6 | 0.2 | _ | (1.5) | |
| $Chamimla^2$ | Sales | 185.2 | 214.1 | 28.9 | 9.8 | 15.7 2.7 | .7 2.7 | 3.4 | - | |
| Chemicals ² | Operating income | 22.4 | 30.1 | 7.8 | 4.0 | | | | (12.0) | |
| Electronics | Sales | 36.4 | 39.8 | 3.5 | 3.1 | (0,2) | 0.5 | 0.5 | 0.7 | - |
| Electronics | Operating income | 1.7 | 3.7 | 2.0 | 1.1 | (0.3) | 0.5 | _ | 1.1 | |
| Llomos | Sales | 125.4 | 134.7 | 9.3 | 1.2 | 0.0 | | 8.1 | - | |
| - | Operating income | 10.8 | 11.9 | 1.1 | 1.3 | 0.0 – | | _ | (0.2) | |
| Construction | Sales | 14.1 | 14.5 | 0.4 | 0.4 | 0.0 | | | - | |
| Materials | Operating income | 1.9 | 1.7 | (0.2) | | | | _ | (0.4) | |

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

² Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

Sales and operating income increase/decrease by business category¹, Oct.–Dec. 2017 vs. 2016 (ii) AsahiKASEI

(¥ billion)

| | | | | Net | | Incre | ase (decrease | e) due to | : |
|--|---------------------|-------------------|-------------------|------------------------|-----------------|-----------------|---|-----------|----------------------------------|
| | | Oct.–Dec. 2016 | Oct.–Dec. 2017 | increase (decrease) | Sales volume | Sales prices | of which, due to foreign exchange | Others | Operating costs and others |
| Health Care | Sales | 34.3 | 36.7 | 2.4 | 0.4 | 0.5 | 0.0 | 1.6 | _ |
| | Operating income | 5.4 | 8.2 | 2.8 | 0.5 | 0.5 | 0.0 | _ | 1.8 |
| Critical Care | Sales | 34.8 | 40.8 | 6.0 | 4.3 | 0.4 | 0.3 | 1.3 | _ |
| Ciffical Care | Operating income | 4.0 | 5.4 | 1.4 | 2.5 | 0.4 | 0.5 | _ | (1.5) |
| Others ² | Sales | 4.5 | 4.4 | (0.1) | (0.1) | | | _ | _ |
| Outers | Operating income | 0.4 | 0.4 | 0.0 | (0.3) | - | _ | _ | 0.4 |
| Corporate expenses and eliminations | Operating loss | (6.5) | (7.9) | (1.3) | _ | _ | _ | _ | (1.3) |
| Consolidated | Sales | 466.1 | 519.8 | 53.7 | 20.9 | 16.8 | 3.8 | 15.9 | _ |
| | Operating income | 43.4 | 56.5 | 13.2 | 9.8 | 10.0 | 5.0 | _ | (13.5) |

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

² Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category.

FY 2016 figures are recalculated in accordance with the new classification.

Sales and operating income increase/decrease by business category¹, Apr.–Dec. 2017 vs. 2016 (i) AsahiKASEI

| (¥ | bil | llion |) |
|----|----------|-------|-----|
| (± | ν II | шон | .) |

| | | | | Net | | Incre | ase (decreas | e) due to | : |
|------------------------|------------------|-------------------|-------------------|------------------------|-----------------|-----------------|---|-----------|----------------------------------|
| | | Apr.–Dec. 2016 | Apr.–Dec. 2017 | increase (decrease) | Sales volume | Sales prices | of which, due to foreign exchange | Others | Operating costs and others |
| | Sales | 93.7 | 100.8 | 7.1 | 3.9 | | | 1.9 | _ |
| Fibers | Operating income | 9.3 | 9.6 | 0.2 | 1.9 | 1.3 | 0.6 | _ | (3.0) |
| | Sales | 520.0 | 589.2 | 69.2 | 13.7 | 10.1 | | 7.5 | _ |
| Chemicals ² | Operating income | 55.6 | 78.7 | 23.1 | 8.5 | 48.1 | 8.5 | _ | (33.5) |
| | Sales | 103.3 | 117.5 | 14.2 | 12.6 | | | 2.4 | _ |
| Electronics | Operating income | 1.4 | 9.3 | 7.8 | 4.1 | (0.8) | 1.9 | _ | 4.5 |
| | Sales | 390.3 | 404.3 | 14.1 | 5.3 | ~ - | | 8.3 | - |
| Homes | Operating income | 35.4 | 36.2 | 0.8 | 2.0 | 0.5 | _ | _ | (1.7) |
| Construction | Sales | 36.7 | 40.6 | 3.9 | 3.2 | | | 0.9 | _ |
| Materials | Operating income | 3.7 | 3.5 | (0.2) | 1.4 | (0.2) | _ | _ | (1.3) |

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

² Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

Sales and operating income increase/decrease by business category¹, Apr.–Dec. 2017 vs. 2016 (ii) AsahiKASEI

(¥ billion)

| | | | | | | Increas | e (decrease | e) due to: | |
|--|-----------------------|----------------------------------|---------|-------------------------------|-----------------|-----------------|--|------------|----------------------------------|
| | | Apr.–Dec. Apr.–Dec. 2016 2017 | | Net increase (decrease) | Sales volume | Sales prices | of which, due to foreign exchange | Others | Operating costs and others |
| | Sales | 102.1 | 103.1 | 1.0 | (2.3) | | 0.1 | 2.4 | _ |
| Health Care | Operating income | 16.1 | 18.1 | 1.9 | (1.2) | 0.9 | 0.1 | _ | 2.2 |
| | Sales | 99.2 | 117.0 | 17.7 | 11.6 | | 0.4 | 5.3 | - |
| Critical Care | e Operating income | 10.8 | 13.9 | 3.1 | 6.6 | 0.8 | 0.4 | _ | (4.3) |
| | Sales | 11.5 | 12.0 | 0.5 | 0.5 | | | _ | _ |
| Others ² | Operating income | 1.3 | 1.1 | (0.2) | (0.1) | _ | _ | _ | (0.1) |
| Corporate expenses and eliminations | Operating loss | (19.5) | (21.1) | (1.6) | _ | | _ | _ | (1.6) |
| | Sales | 1,356.8 | 1,484.5 | 127.7 | 48.5 | | 11.4 | 28.7 | _ |
| | Operating income | 114.1 | 149.2 | 35.1 | 23.3 | 50.5 | 50.5 11.4 | | (38.8) |

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

² Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category.

FY 2016 figures are recalculated in accordance with the new classification.



Forecast for fiscal year 2017

Consolidated operating performance forecast AsahiKASEI

(¥ billion)

| | | FY 2016 | | | FY 2017 | ⁷ revised f | orecast | | FY 2017 | |
|--|--------|---------|---------|--------|-----------|------------------------|----------------|---------|---------------------|------------------------|
| | H1 | H2 | Total | H1 | Oct.–Dec. | Jan.–Mar. | H2 forecast | Total | forecast in Nov. | Increase (decrease) |
| Net sales | 890.7 | 992.3 | 1,883.0 | 964.7 | 519.8 | 565.5 | 1,085.3 | 2,050.0 | 2,000.0 | 50.0 |
| Operating income | 70.8 | 88.5 | 159.2 | 92.7 | 56.5 | 45.8 | 102.3 | 195.0 | 183.0 | 12.0 |
| Ordinary income | 69.9 | 90.8 | 160.6 | 98.2 | 62.4 | 47.5 | 109.8 | 208.0 | 192.0 | 16.0 |
| Net income attributable to owners of the parent | 52.9 | 62.1 | 115.0 | 70.9 | 69.5 | 28.7 | 98.1 | 169.0 | 140.0 | 29.0 |
| Key operating factors | | | | | | | | | | |
| Naphtha price (¥/kL, domestic) | 31,450 | 37,900 | 34,675 | 37,600 | 44,600 | 49,200 | 46,900 | 42,250 | 40,800 | 1,450 |
| ¥/US\$ exchange rate (market average) | 105 | 112 | 108 | 111 | 113 | 110 | 111 | 111 | 111 | 1 |
| ¥/€ exchange rate (market average) | 118 | 119 | 119 | 126 | 133 | 130 | 132 | 129 | 128 | 1 |

| | FY 2016 | FY 2017 |
|---------------------|---------|------------------|
| Dividends per share | ¥24 | ¥28 (planned) |
| Payout ratio | 29.1% | 23.1% |



(¥ billion)

| FY 2016 | | | | | FY 2012 | 7 revised fo | orecast | | FY 2017 | Increase |
|------------------------|-------|-------|---------|-------|-----------|--------------|----------|---------|---------------------|------------|
| | H1 | H2 | Total | H1 | | 1 | H2 | Total | forecast in Nov. | (decrease) |
| | | | | | Oct.–Dec. | Jan.–Mar. | forecast | а | Ь | а-в |
| Fibers | 62.3 | 63.4 | 125.7 | 66.1 | 34.7 | 34.2 | 68.9 | 135.0 | 135.0 | _ |
| Chemicals ¹ | 334.8 | 378.0 | 712.8 | 375.2 | 214.1 | 217.8 | 431.8 | 807.0 | 761.0 | 46.0 |
| Electronics | 66.9 | 72.5 | 139.4 | 77.7 | 39.8 | 36.5 | 76.3 | 154.0 | 154.0 | _ |
| Homes | 264.8 | 305.3 | 570.2 | 269.6 | 134.7 | 183.7 | 318.4 | 588.0 | 588.0 | _ |
| Construction Materials | 22.6 | 26.2 | 48.8 | 26.1 | 14.5 | 12.4 | 26.9 | 53.0 | 53.0 | _ |
| Health Care | 67.8 | 66.1 | 133.9 | 66.3 | 36.7 | 32.9 | 69.7 | 136.0 | 136.0 | _ |
| Critical Care | 64.5 | 71.7 | 136.2 | 76.2 | 40.8 | 43.0 | 83.8 | 160.0 | 156.0 | 4.0 |
| Others ¹ | 7.0 | 9.0 | 16.0 | 7.6 | 4.4 | 5.0 | 9.4 | 17.0 | 17.0 | _ |
| Consolidated | 890.7 | 992.3 | 1,883.0 | 964.7 | 519.8 | 565.5 | 1,085.3 | 2,050.0 | 2,000.0 | 50.0 |

¹ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.



(¥ billion)

| | | FY 2016 | | | FY 201 | 7 revised for | ecast | | FY 2017 | Increase |
|-------------------------------------|--------|---------|--------|--------|---------|---------------|----------|--------|---------------------|------------|
| | H1 | H2 | Total | H1 | | | H2 | Total | forecast in Nov. | (decrease) |
| | | | | | OctDec. | Jan.–Mar. | forecast | а | b | a-b |
| Fibers | 6.0 | 5.7 | 11.7 | 6.6 | 3.0 | 2.9 | 5.9 | 12.5 | 12.5 | _ |
| Chemicals ² | 33.3 | 41.1 | 74.4 | 48.6 | 30.1 | 19.3 | 49.4 | 98.0 | 88.5 | 9.5 |
| Electronics | (0.3) | 2.8 | 2.5 | 5.6 | 3.7 | (0.3) | 3.4 | 9.0 | 7.5 | 1.5 |
| Homes | 24.6 | 34.9 | 59.5 | 24.3 | 11.9 | 23.8 | 35.7 | 60.0 | 60.0 | _ |
| Construction Materials | 1.8 | 2.6 | 4.5 | 1.8 | 1.7 | 1.0 | 2.7 | 4.5 | 4.5 | _ |
| Health Care | 10.7 | 6.4 | 17.1 | 9.9 | 8.2 | 0.9 | 9.1 | 19.0 | 18.0 | 1.0 |
| Critical Care | 6.8 | 8.0 | 14.8 | 8.5 | 5.4 | 5.6 | 11.0 | 19.5 | 18.5 | 1.0 |
| Others ² | 0.9 | 1.2 | 2.0 | 0.7 | 0.4 | 0.4 | 0.8 | 1.5 | 1.5 | _ |
| Corporate expenses and eliminations | (13.0) | (14.1) | (27.1) | (13.3) | (7.9) | (7.9) | (15.7) | (29.0) | (28.0) | (1.0) |
| Consolidated | 70.8 | 88.5 | 159.2 | 92.7 | 56.5 | 45.8 | 102.3 | 195.0 | 183.0 | 12.0 |

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

² Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category.

FY 2016 figures are recalculated in accordance with the new classification.



| Sales Torecast | | | | | | | | | | | |
|-----------------------|---------|-------|---------|-------|-----------|--------------|----------|---------|---------------------|------------|--|
| | FY 2016 | | | | FY 201 | 7 revised fo | orecast | | | Increase | |
| | H1 | H2 | Total | H1 | | | H2 | Total | forecast in Nov. | (decrease) | |
| | | | | | Oct.–Dec. | Jan.–Mar. | forecast | а | b | а-в | |
| Material ¹ | 464.0 | 513.9 | 977.9 | 518.9 | 288.6 | 288.5 | 577.1 | 1,096.0 | 1,050.0 | 46.0 | |
| Homes | 287.5 | 331.5 | 619.0 | 295.7 | 149.3 | 196.0 | 345.3 | 641.0 | 641.0 | - | |
| Health Care | 132.3 | 137.8 | 270.1 | 142.5 | 77.5 | 76.0 | 153.5 | 296.0 | 292.0 | 4.0 | |
| Others ¹ | 7.0 | 9.0 | 16.0 | 7.6 | 4.4 | 5.0 | 9.4 | 17.0 | 17.0 | _ | |
| Consolidated | 890.7 | 992.3 | 1,883.0 | 964.7 | 519.8 | 565.5 | 1,085.3 | 2,050.0 | 2,000.0 | 50.0 | |

Sales forecast

(¥ billion)

(¥ hillion)

Operating income forecast

| | FY 2016 | | | | FY 201 | FY 2017 | Increase | | | |
|-------------------------------------|---------|--------|--------|--------|-----------|-----------|----------|--------|---------------------|------------|
| | H1 | H2 | Total | H1 | | | | Total | forecast in Nov. | (decrease) |
| | | | | | Oct.–Dec. | Jan.–Mar. | forecast | а | Ь | а-в |
| Material ¹ | 38.9 | 49.6 | 88.5 | 60.7 | 36.8 | 22.0 | 58.8 | 119.5 | 108.5 | 11.0 |
| Homes | 26.5 | 37.6 | 64.1 | 26.1 | 13.3 | 25.1 | 38.4 | 64.5 | 64.5 | - |
| Health Care | 17.6 | 14.4 | 31.9 | 18.4 | 13.5 | 6.5 | 20.1 | 38.5 | 36.5 | 2.0 |
| Others ¹ | 0.9 | 1.2 | 2.0 | 0.7 | 0.4 | 0.4 | 0.8 | 1.5 | 1.5 | - |
| Corporate expenses and eliminations | (13.1) | (14.2) | (27.3) | (13.3) | (7.5) | (8.2) | (15.7) | (29.0) | (28.0) | (1.0) |
| Consolidated | 70.8 | 88.5 | 159.2 | 92.7 | 56.5 | 45.8 | 102.3 | 195.0 | 183.0 | 12.0 |

¹ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Material business category. FY 2016 figures are recalculated in accordance with the new classification.



Appendix

Quarterly sales by business category



| | | FY 2 | 2016 | | | FY 2017 | | FY 2017 | | | | |
|------------------------|-------|-------|-------|-------|-------|---------|-------|----------|--|--|--|--|
| | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | | | | |
| | QI | Q2 | Q3 | QŦ | QI | Q2 | Q3 | forecast | | | | |
| Fibers | 30.9 | 31.4 | 31.4 | 32.0 | 32.0 | 34.1 | 34.7 | 34.2 | | | | |
| Chemicals ¹ | 167.0 | 167.9 | 185.2 | 192.8 | 178.3 | 196.8 | 214.1 | 217.8 | | | | |
| Electronics | 32.2 | 34.7 | 36.4 | 36.1 | 36.5 | 41.2 | 39.8 | 36.5 | | | | |
| Homes | 115.7 | 149.1 | 125.4 | 179.9 | 115.6 | 154.0 | 134.7 | 183.7 | | | | |
| Construction Materials | 10.3 | 12.3 | 14.1 | 12.1 | 12.6 | 13.5 | 14.5 | 12.4 | | | | |
| Health Care | 34.5 | 33.3 | 34.3 | 31.8 | 32.7 | 33.6 | 36.7 | 32.9 | | | | |
| Critical Care | 32.2 | 32.3 | 34.8 | 37.0 | 37.3 | 38.8 | 40.8 | 43.0 | | | | |
| Others ¹ | 2.9 | 4.1 | 4.5 | 4.5 | 3.6 | 4.0 | 4.4 | 5.0 | | | | |
| Total | 425.8 | 464.9 | 466.1 | 526.1 | 448.7 | 516.0 | 519.8 | 565.5 | | | | |

¹ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

Quarterly operating income (loss) by business category¹



| | | FY 2 | 2016 | | | FY 2017 | | FY 2017 | | | | |
|--|-------|-------|------------|-------|-------|---------|-------|----------|--|--|--|--|
| | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | | | | |
| | Q1 | Q2 | Q 0 | ×1 | Q1 | Q2 | 20 | forecast | | | | |
| Fibers | 3.3 | 2.7 | 3.4 | 2.3 | 3.5 | 3.1 | 3.0 | 2.9 | | | | |
| Chemicals ² | 14.7 | 18.6 | 22.4 | 18.8 | 22.5 | 26.0 | 30.1 | 19.3 | | | | |
| Electronics | (0.1) | (0.2) | 1.7 | 1.0 | 2.0 | 3.6 | 3.7 | (0.3) | | | | |
| Homes | 7.8 | 16.8 | 10.8 | 24.1 | 6.9 | 17.3 | 11.9 | 23.8 | | | | |
| Construction Materials | 0.9 | 1.0 | 1.9 | 0.8 | 0.7 | 1.1 | 1.7 | 1.0 | | | | |
| Health Care | 6.8 | 4.0 | 5.4 | 1.0 | 5.3 | 4.6 | 8.2 | 0.9 | | | | |
| Critical Care | 2.8 | 4.0 | 4.0 | 4.0 | 3.7 | 4.8 | 5.4 | 5.6 | | | | |
| Others ² | 0.2 | 0.7 | 0.4 | 0.7 | 0.0 | 0.6 | 0.4 | 0.4 | | | | |
| Corporate expenses and eliminations | (6.4) | (6.6) | (6.5) | (7.6) | (6.9) | (6.4) | (7.9) | (7.9) | | | | |
| Total | 29.9 | 40.9 | 43.4 | 45.1 | 37.9 | 54.8 | 56.5 | 45.8 | | | | |

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

² Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

Overseas sales by business category, Apr.–Dec. 2016 and 2017



(¥ billion)

| | Apr.–Dec. 2016 | | Δ | D_{0} | | | | |
|---|----------------|------------|------------|--------------|-----------|---------------------|----------|------------|
| | Ар | r.–Dec. 20 | 10 | Apr | .–Dec. 20 | Increase (decrease) | | |
| | Total sales | Overseas | | Total sales | Overseas | | in overs | seas sales |
| | 1 otar bareb | sales | % of total | i otar bareb | sales | % of total | | % change |
| Fibers | 93.7 | 39.0 | 41.6% | 100.8 | 44.3 | 43.9% | 5.3 | +13.5% |
| Chemicals ¹ | 520.0 | 242.3 | 46.6% | 589.2 | 288.6 | 49.0% | 46.3 | +19.1% |
| Electronics | 103.3 | 71.4 | 69.1% | 117.5 | 81.4 | 69.3% | 10.0 | +14.0% |
| Homes | 390.3 | _ | _ | 404.3 | _ | _ | _ | _ |
| Construction Materials | 36.7 | 0.0 | 0.0% | 40.6 | 0.0 | 0.0% | 0.0 | _ |
| Health Care | 102.1 | 29.2 | 28.6% | 103.1 | 31.0 | 30.0% | 1.7 | +5.9% |
| Critical Care | 99.2 | 98.2 | 98.9% | 117.0 | 115.5 | 98.7% | 17.3 | +17.6% |
| Others ¹ | 11.5 | 1.8 | 15.4% | 12.0 | 2.7 | 22.1% | 0.9 | +49.2% |
| Total | 1,356.8 | 481.9 | 35.5% | 1,484.5 | 563.4 | 38.0% | 81.5 | +16.9% |
| Sales to East Asia ² | | 216.2 | 15.9% | | 255.4 | 17.2% | 39.1 | +18.1% |
| of which, sales to China | | 124.3 | 9.2% | | 140.6 | 9.5% | 16.2 | +13.1% |
| Sales, excluding Homes and Construction Materials | 929.9 | 481.9 | 51.8% | 1,039.6 | 563.4 | 54.2% | | |

¹ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Material business category.

FY 2016 figures are recalculated in accordance with the new classification


² China, Korea, and Taiwan.

Statements of comprehensive income

Asahi KASEI

| (¥ billion) | | | | | | | |
|---|--------------|--------------|-------------|--|--|--|--|
| | 2016 | 2017 | Increase | | | | |
| | Apr.–Dec. | Apr.–Dec. | (decrease) | | | | |
| a: Net income | 91.0 | 141.9 | 50.9 | | | | |
| Net increase or decrease in unrealized gain on other securities | 16.6 | 20.6 | 4.1 | | | | |
| Deferred gains or losses on hedges | 0.2 | (0.0) | (0.2) | | | | |
| Foreign currency translation adjustment | 8.2 | 20.9 | 12.7 | | | | |
| Remeasurements of defined benefit plans | 6.3 | 5.9 | (0.4) | | | | |
| Share of other comprehensive income of affiliates accounted for using equity method | 0.3 | 1.5 | 1.2 | | | | |
| b: Other comprehensive income | 31.6 | 48.9 | 17.3 | | | | |
| Comprehensive income [a+b] | 122.6 | 190.8 | 68.2 | | | | |
| Comprehensive income attributable to owners of the parent Comprehensive income attributable to non-controlling interests | 121.1 1.5 | 188.7 2.1 | 67.7 0.5 | | | | |

Fibers



Review of operations

Impact of higher feedstock costs. Strong performance of Lamous microfiber suede. Sales increase and slight operating income increase.

Asahi **KASEI**


Highlights

- September, decision to increase production capacity for Lamous microfiber suede in Nobeokashi, Miyazaki, Japan.
- January, decision to increase production capacity for Leona nylon 66 filament in Nobeoka-shi, Miyazaki, Japan.

¹ Increase (decrease) in sales prices excluding impact of foreign exchange. ² Impact of foreign exchange on sales prices.

Chemicals¹

Asahi **KASEI**



¹ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

² Increase (decrease) in sales prices excluding impact of foreign exchange.

³ Impact of foreign exchange on sales prices.

Review of operations

Petrochemicals:

Improved market prices for acrylonitrile. Sales and operating income increase.

Performance polymers:

Improved terms of trade for synthetic rubber. Firm sales of engineering plastics. Sales and operating income increase.


Performance materials & consumables:

Increased shipments of ion-exchange membranes and electronic materials. Firm performance of Saran Wrap cling film and other consumables. Sales and operating income increase.

- July, decision to increase production capacity for S-SBR for fuel-efficient tires in Singapore.
- August, decsion to construct a new plant for plastic compounds in Changshu, Jiangsu, China, with start-up scheduled in early 2020.
- September, establishment of joint ventures with China National Bluestar (Group) Co., Ltd., for the integrated production and sale of Xyron modified polyphenylene ether, including its intermediate materials 2,6-xylenol and polyphenylene ether, in Nantong, Jiangsu, China.
- October, selection of Microza hollow-fiber membrane for a seawater desalination plant in Doha, Kuwait City, Kuwait, representing the company's largest-scale hollow-fiber filtration membrane order ever received.

Electronics

Asahi **KASEI**



¹ Increase (decrease) in sales prices excluding impact of foreign exchange.

² Impact of foreign exchange on sales prices.

Review of operations

Separators:

Considerably increased shipments of each battery separator product, centered on Li-ion battery separator. Sales and operating income increase. Electronic devices:

Firm sales of electronic devices for camera modules and magnetic sensors for household appliances. Sales and operating income increase.

- January, decision to increase production capacity for Celgard dry-process Li-ion battery separator in North Carolina, the US, by 150 million m²/year with start-up scheduled in H2 2018.
- January, decision to increase production capacity for Hipore wet-process Li-ion battery separator in Moriyama, Shiga, Japan, by 90 million m²/year with start-up scheduled in H1 2020.
- January, agreement to acquire shares of Senseair AB, a Swedish manufacturer of gas sensor modules.

Homes (i)





Results by product category

| | Apr.–D | ec. 2016 | Apr.–D | ec. 2017 | Increase (decrease) | |
|--|--------|------------------|--------|------------------|------------------------|------------------|
| | Sales | Operating income | Sales | Operating income | Sales | Operating income |
| Order-built homes, etc. (Asahi Kasei Homes) | 270.7 | 23.0 | 268.7 | 21.8 | (2.0) | (1.2) |
| Real estate (Asahi Kasei Realty & Residence) | 77.7 | 6.9 | 92.7 | 8.6 | 14.9 | 1.7 |
| Remodeling (Asahi Kasei Reform) | 41.9 | 4.0 | 41.2 | 4.1 | (0.7) | 0.1 |
| Other housing-related, etc. | (0.1) | 1.5 | 1.7 | 1.6 | 1.9 | 0.2 |
| Total | 390.3 | 35.4 | 404.3 | 36.2 | 14.1 | 0.8 |

(¥ billion)

Review of operations

Order-built homes:

- Decreased deliveries of Hebel Maison apartment buildings. Increased SG&A expenses such as advertising expenses. Sales and operating income decrease.
- Value of new orders flat year-on-year. Increased value of new orders for multi-dwelling homes with firm demand for apartment buildings, but decreased value for unit homes.

Real estate, remodeling and others:

Firm performance of rental management and condominium construction in real estate. Solid performance in remodeling. Sales and operating income increase.

- May, new high-durability double-layer insulation system adopted in all products.
- June, start of sales of Hebel Haus Cubic Roomy, a new model of the main product series of Hebel Haus Cubic two-story unit homes.
- August, formation of capital alliance with McDonald Jones Homes Pty Ltd, an Australian company which constructs and sells unit homes.
- November, launch of promotion to commemorate 50th anniversary of production of Hebel autoclaved aerated concrete in Japan. 28

Homes (ii)

Sales¹ and order trends


(¥ billion, % indicates year-on-year comparison)

| | | | | | | | | 、 、 | - | 5 | 5 | <u> </u> |
|------|-----------------|-------------|-----------|--------------------------------|--------------------|-------------------|-------------------------|--------|------------|-------|----------------|----------|
| | | Value of ne | ew orders | Sales of order- | | Sales of re | eal estate ¹ | | Sales of | Other | Other | Order |
| | | during t | | built homes, etc. ¹ | Pre-built homes | Rental housing | Other | Total | remodeling | sales | Consolidated | backlog |
| FY13 | H1 | 251.9 | (+21.4%) | 181.0 (+12.1%) | 4.5 | 26.2 | 1.4 | 32.1 | 24.5 | 0.8 | 238.4 (+11.9%) | 519.9 |
| | H2 | 169.4 | (-17.3%) | 213.1 (+3.5%) | 24.8 | 27.9 | 1.1 | 53.7 | 28.1 | 1.1 | 296.0 (+8.4%) | 481.5 |
| | annual | 421.3 | (+2.2%) | 394.1 (+7.3%) | 29.3 | 54.1 | 2.5 | 85.8 | 52.6 | 1.9 | 534.4 (+9.9%) | |
| FY14 | H1 | 217.6 | (-13.6%) | 187.9 (+3.9%) | 9.8 | 29.3 | 1.4 | 40.6 | 26.3 | 1.1 | 256.0 (+7.4%) | 516.3 |
| | H2 | 208.0 | (+22.8%) | 216.2 (+1.5%) | 18.0 | 31.8 | 1.6 | 51.4 | 27.3 | 0.9 | 295.8 (-0.1%) | 514.5 |
| | annual | 425.7 | (+1.0%) | 404.2 (+2.6%) | 27.8 | 61.1 | 3.1 | 92.0 | 53.6 | 2.0 | 551.8 (+3.3%) | |
| FY15 | H1 | 217.3 | (-0.2%) | 183.8 (-2.2%) | 10.4 | 33.5 | 1.7 | 45.6 | 27.8 | 0.9 | 258.0 (+0.8%) | 554.6 |
| | H2 | 183.1 | (-12.0%) | 227.7 (+5.3%) | 27.7 | 39.0 | 1.8 | 68.4 | 28.1 | 0.7 | 325.0 (+9.9%) | 513.1 |
| | annual | 400.4 | (-5.9%) | 411.5 (+1.8%) | 38.1 | 72.5 | 3.5 | 114.1 | 55.9 | 1.6 | 583.0 (+5.7%) | |
| FY16 | H1 | 206.6 | (-4.9%) | 183.5 (-0.1%) | 11.8 | 41.2 | 1.8 | 54.8 | 27.0 | (0.5) | 264.8 (+2.6%) | 538.8 |
| | Q3 | 89.5 | (+5.5%) | 87.2 (-7.3%) | 1.0 | 21.1 | 0.8 | 23.0 | 14.8 | 0.4 | 125.4 (-13.2%) | 542.7 |
| | H2 | 194.3 | (+6.1%) | 220.8 (-3.1%) | 9.5 | 43.5 | 1.6 | 54.6 | 29.1 | 0.8 | 305.3 (-6.1%) | 515.8 |
| | annual | 400.9 | (+0.1%) | 404.3 (-1.8%) | 21.3 | 84.7 | 3.4 | 109.4 | 56.1 | 0.4 | 570.2 (-2.2%) | |
| FY17 | H1 | 193.1 | (-6.5%) | 182.7 (-0.4%) | 12.0 | 45.3 | 1.6 | 59.0 | 26.8 | 1.1 | 269.6 (+1.8%) | 528.9 |
| | Q3 | 104.1 | (+16.4%) | 86.0 (-1.4%) | 9.2 | 23.2 | 1.3 | 33.7 | 14.4 | 0.6 | 134.7 (+7.4%) | 548.5 |
| | H2 forecast | 215.8 | (+11.0%) | 223.3 (+1.1%) | 15.0 | 47.7 | 2.4 | 65.0 | 28.7 | 1.4 | 318.4 (+4.3%) | 524.6 |
| ä | annual forecast | 408.8 | (+2.0%) | 406.0 (+0.4%) | 27.0 | 93.0 | 4.0 | 124.0 | 55.5 | 2.5 | 588.0 (+3.1%) | |

¹ As the rental management operation of Asahi Kasei Homes was transferred to Asahi Kasei Realty & Residence, the corresponding sales previously included in order-built homes, etc., are combined with rental housing under real estate beginning with H2 2015.

Asahi **KASEI**

Construction Materials



others

Review of operations

Firm shipments of Neoma Foam phenolic foam insulation panels. Impact of higher feedstock costs. Sales increase, but operating income flat.


Highlights

•January, announcement to launch sales of Neoma Zeus, a new phenolic foam insulation panel with higher insulation performance than previous products.

Asahi**KASEI**

Health Care (i)

Asahi KASEI



¹ Increase (decrease) in sales prices excluding impact of foreign exchange. ² Impact of foreign exchange on sales prices.

Review of operations

Pharmaceuticals:

Increased shipments of Teribone osteoporosis drug. Decreased shipments centering on Flivas agent for treatment of benign prostatic hyperplasia due to competition from generics. Sales and operating income decrease.

Devices:

Firm performance of each business. Impact of weaker yen. Sales and operating income increase.

- May, approval for an extension of the maximum duration of treatment for the osteoporosis drug Teribone 56.5 µg subcutaneous injection.
- June, application for import drug registration for Flivas (naftopidil) in China.
- October, announcement of an open competition for new-drug development proposals from researchers at domestic and overseas universities, research institutions, and corporations.
- October, receipt of 510(k) clearance from the US Food and Drug Administration for Lucica Glycated Albumin-L, an in vitro diagnostic assay kit for glycated albumin formulated for the US market.
- November, announcement of Phase III clinical study results of famciclovir for the treatment of recurrent herpes simplex.
- December, agreement with Sanofi for marketing of Kevzara Subcutaneous Injection, a treatment for rheumatoid arthritis in Japan; launch in February.
- December, decision to construct a new spinning plant for Planova filters in Nobeoka-shi, Miyazaki, Japan.

Health Care (ii)

Asahi**KASEI**

| S | Sales of Health Care business category (¥ billion) | | | | | | | | |
|---|--|------------------------------|-----------|---------|-----------|-----------|-------|--|--|
| | | | | FY 2016 | | FY 2017 | | | |
| | | | | 1 | | | | | |
| | | Oct.–Dec. | Apr.–Dec. | Total | Oct.–Dec. | Apr.–Dec. | | | |
| | | Domestic pharamaceuticals | 16.3 | 47.5 | 61.5 | 16.5 | 47.0 | | |
| | | Others | 1.5 | 4.9 | 6.4 | 1.1 | 3.9 | | |
| | Asa | hi Kasei Pharma consolidated | 17.8 | 52.4 | 67.8 | 17.6 | 50.9 | | |
| | Dev | vices ¹ | 16.6 | 49.7 | 66.1 | 19.1 | 52.2 | | |
| - | Fotal | | 34.4 | 102.1 | 133.9 | 36.7 | 103.1 | | |

¹ Asahi Kasei Medical and its affiliate companies.

Main pharmaceuticals domestic sales

(¥ billion)

| | | FY 2016 | FY 2017 | | |
|-------------|-----------|-----------|---------|---------|-----------|
| | | | | | |
| | Oct.–Dec. | Apr.–Dec. | Total | OctDec. | Apr.–Dec. |
| Teribone | 6.1 | 18.1 | 23.9 | 7.2 | 20.5 |
| Recomodulin | 3.7 | 10.0 | 12.6 | 3.5 | 9.3 |
| Flivas | 1.5 | 4.7 | 5.9 | 1.3 | 3.7 |
| Elcitonin | 1.1 | 3.4 | 4.4 | 0.9 | 2.8 |
| Bredinin | 1.1 | 3.3 | 4.2 | 1.0 | 2.9 |

32

Health Care (iii)




Pharmaceutical pipeline

| Development stage | Code name, form, generic name | Classifications | Indication | Region | Origin | Remarks |
|-----------------------------------|---|-------------------|--|----------------------------------|----------|---------------------------------|
| Phase III | ART-123, injection, recombinant thrombomodulin alpha | Anticoagulant | Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) | Japan | In-house | Additional indication |
| | MN-10-T, autoinjection, teriparatide acetate | Osteoporosis drug | Osteoporosis with high risk of fracture | Japan | In-house | New formulation; new dose |
| Phase II | ART-123, injection, recombinant thrombomodulin alpha | Anticoagulant | Chemotherapy- induced peripheral neuropathy (CIPN) | Japan | In-house | Additional indication |
| Pending approval (overseas) | Flivas, tablet, naftopidil | Dysuria treatment | Benign prostatic hyperplasia | China | In-house | |
| Phase III (overseas) | ART-123, injection, recombinant thrombomodulin alpha | Anticoagulant | Severe sepsis with coagulopathy | United States, Europe, etc | In-house | |
| | HE-69, tablet, mizoribine | Immunosuppressant | Lupus nephritis, nephrotic syndrome | China | In-house | Additional indication |

Critical Care

Asahi KASEI



Review of operations

Increased shipments of defibrillators for professional use. Firm performance of LifeVest wearable defibrillator business. Sales and operating income increase.

Financial performance of Critical Care business category

(\$ million)

| P | - | | | | | | , , |
|----------|---|------|-------|---------|------|-------|----------|
| | | Oct | Apr.– | FY 2016 | Oct | Apr.– | FY 2017 |
| | | Dec. | Dec. | | Dec. | Dec. | forecast |
| Net sale | es | 318 | 930 | 1,256 | 361 | 1,047 | 1,438 |
| Gross | Gross operating income before PPA ¹ impact | | | 259 | 78 | 216 | 297 |
| Amort | Amortization/depreciation from PPA ¹ revaluation | | (92) | (122) | (31) | (92) | (122) |
| | Goodwill | (19) | (56) | (75) | (19) | (56) | (75) |
| | Other intangible assets, etc. | (12) | (35) | (47) | (12) | (35) | (47) |
| Consoli | idated operating income | 36 | 101 | 136 | 48 | 125 | 175 |

¹ Purchase price allocation.